NCT04450407

A Study of LY3209590 in Participants With Type 1 Diabetes

A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 266 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.

Conditions

• Type 1 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	LY3209590	Administered SC
DRUG	Insulin Degludec	Administered SC

Timeline

• Start date: 2020-07-06
• Primary completion: 2021-10-01
• Completion: 2021-10-01
• First posted: 2020-06-29
• Last updated: 2022-10-27
• Results posted: 2022-10-27

Locations

54 sites across 5 countries: United States, Austria, Germany, Puerto Rico, Spain

Regulatory

• FDA-regulated drug study